Revance Therapeutics Inc Revenue Growth Rates (RVNC), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Revance Therapeutics Inc   (NASDAQ: RVNC)
 

RVNC's Revenue Growth by Quarter and Year

Revance Therapeutics Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

RVNC Revenue (in millions $) FY 2024 FY 2023 FY 2022 FY 2021
4th Quarter December -
3rd Quarter September 59.88
2nd Quarter June 65.39
1st Quarter March 51.94
FY 177.21

RVNCs Annual Revenue
Revance Therapeutics Inc 's Revenue in the fiscal year 2023 $ 234.04 millions
Revance Therapeutics Inc 's Revenue in the fiscal year 2022 $ 132.57 millions
Revance Therapeutics Inc 's Revenue in the fiscal year 2021 $ 77.80 millions
Revance Therapeutics Inc 's Revenue in the fiscal year 2020 $ 15.33 millions
Revance Therapeutics Inc 's Revenue in the fiscal year 2019 $ 0.41 millions




RVNC Revenue third quarter 2024 Y/Y Growth Comment
Revance Therapeutics Inc reported Revenue growth of 5.46% year on year in the third quarter 2024, to $ 59.88 millions, this is lower than Revance Therapeutics Inc 's recent average Revenue surge of 1325.07%.

Looking into third quarter 2024 results within Major Pharmaceutical Preparations industry 133 other companies have achieved higher Revenue growth. While Revance Therapeutics Inc ' s Revenue increase of 5.46% ranks overall at the positon no. 1887 in the third quarter 2024.


RVNC Revenue ( Y/Y Growth %) 2024
 2023 2022 2021
4th Quarter December - 39.82 % 92.37 % 133.15 %
3rd Quarter September 5.46 % 95.66 % 46.94 % 414.32 %
2nd Quarter June 12.49 % 104.9 % 50.9 % 6166.67 %
1st Quarter March 5.29 % 95.29 % 89.92 % 22066.67 %
FY   - 76.54 % 70.4 % -

Financial Statements
Revance Therapeutics Inc 's third quarter 2024 Revenue $ 59.88 millions RVNC's Income Statement
Revance Therapeutics Inc 's third quarter 2023 Revenue $ 56.78 millions Quarterly RVNC's Income Statement


RVNC Revenue (Quarter on Quarter Growth %)

 2024
 2023 2022 2021
4th Quarter December - 22.93 % 72.02 % 31.39 %
3rd Quarter September -8.43 % -2.32 % 2.29 % 5.05 %
2nd Quarter June 25.9 % 17.84 % 12.31 % 41.35 %
1st Quarter March -25.59 % -1.18 % -2.66 % 19.5 %
FY (Year on Year)   - 76.54 % 70.4 % -


Back to RVNC Growth rate Comparisons >> Back to RVNC Growth rate Comparisons >>


Revenue third quarter 2024 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #134
Healthcare Sector #355
Overall #1887

Revenue Y/Y Growth Statistics
High Average Low
22829.31 % 1325.07 % -100 %
(Jun 30 2021)   (March 31, 2016)
Revenue third quarter 2024 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #134
Healthcare Sector #355
Overall #1887
Revenue Y/Y Growth Statistics
High Average Low
22829.31 % 1325.07 % -100 %
(Jun 30 2021)   (March 31, 2016)

Revenue by Quarter for the Fiscal Years 2021, 2022, 2023, 2024

Revance Therapeutics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
1182.61 % 62.64 % -100 %
(Sep 30 2020)  


RVNC's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2024 Revance Therapeutics Inc disclosed drop in Revenue from the second quarter by -8.43% to $ 59.88 millions, from $ 65.39 millions achived in the previous reporting period.

But that's not important problem, as Revance Therapeutics Inc 's Revenue generally seem to plunge in this quarter.

Within Major Pharmaceutical Preparations industry 179 other companies have achieved higher Revenue quarter on quarter growth. While Revance Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 3512.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #180
Healthcare Sector #513
Overall #3512
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #180
Healthcare Sector #513
Overall #3512
Revenue Q/Q Growth Statistics
High Average Low
1182.61 % 62.64 % -100 %
(Sep 30 2020)  


RVNC's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2024 Revance Therapeutics Inc disclosed drop in Revenue from the second quarter by -8.43% to $ 59.88 millions, from $ 65.39 millions achived in the previous reporting period.

But that's not important problem, as Revance Therapeutics Inc 's Revenue generally seem to plunge in this quarter.

Within Major Pharmaceutical Preparations industry 179 other companies have achieved higher Revenue quarter on quarter growth. While Revance Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 3512.


Revance Therapeutics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2024)		 12 Months Ending
(Jun 30 2024)		 12 Months Ending
(Mar 31 2024)		 12 Months Ending
(Dec 31 2023)		 12 Months Ending
(Sep 30 2023)
Cumulative Revenue 12 Months Ending $ 247.00 $ 243.90 $ 236.64 $ 234.04 $ 214.16
Y / Y Revenue Growth (TTM) 15.33 % 30.85 % 51.08 % 76.55 % 97.21 %
Year on Year Revenue Growth Overall Ranking # 98 # 107 # 87 # 97 # 212
Seqeuential Revenue Change (TTM) 1.27 % 3.07 % 1.11 % 9.28 % 14.89 %
Seq. Revenue Growth (TTM) Overall Ranking # 808 # 534 # 469 # 381 # 1404


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Sep 30 2024 period, Revance Therapeutics Inc 's cumulative twelve months Revenue were $ 247 millions, company would post below average annual Revenue growth of 14.89% year on year, if the fiscal year would end at Sep 30 2024.
A slow-down in the Revance Therapeutics Inc 's Revenue growth from the 65.39% growth in Jun 30 2024.

In the Healthcare sector 44 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 98, from total ranking in previous quarter at 107.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 86
Healthcare Sector # 45
Overall # 98

Revenue TTM Y/Y Growth Statistics
High Average Low
9467.28 %
 577.39 %
-21.67 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 86
Sector # 206
S&P 500 # 808
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Sep 30 2024 period, Revance Therapeutics Inc 's cumulative twelve months Revenue were $ 247 millions, company would post below average annual Revenue growth of -21.67% year on year, if the fiscal year would end at Sep 30 2024.
A slow-down in the Revance Therapeutics Inc 's Revenue growth from the 65.39% growth in Jun 30 2024.

In the Healthcare sector 44 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 98, from total ranking in previous quarter at 107.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 86
Healthcare Sector # 45
Overall # 98

Revenue TTM Y/Y Growth Statistics
High Average Low
9467.28 %
577.39 %
-21.67 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 86
Sector # 206
S&P 500 # 808




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
RVNC's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue drop for the quarter ending Sep 30 2024 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2024
Emmaus Life Sciences Inc 9.17%$ 9.167 millions
Artivion Inc 8.87%$ 8.868 millions
Haemonetics Corporation8.80%$ 8.796 millions
Acadia Healthcare Company Inc 8.70%$ 8.703 millions
Emergent Biosolutions Inc 8.61%$ 8.614 millions
Jazz Pharmaceuticals Plc8.52%$ 8.520 millions
Bristol myers Squibb Company8.44%$ 8.444 millions
Quest Diagnostics Inc8.41%$ 8.410 millions
Siga Technologies Inc8.39%$ 8.388 millions
Sotera Health Company8.38%$ 8.381 millions
Medpace Holdings Inc 8.29%$ 8.288 millions
Tango Therapeutics Inc 8.15%$ 8.153 millions
Cytek Biosciences Inc 8.11%$ 8.112 millions
Hca Healthcare Inc 7.86%$ 7.858 millions
Cytosorbents Corporation7.84%$ 7.840 millions
Merit Medical Systems Inc7.72%$ 7.721 millions
Karyopharm Therapeutics Inc 7.70%$ 7.704 millions
Theravance Biopharma inc 7.49%$ 7.487 millions
Chemed Corporation7.38%$ 7.378 millions
Labcorp Holdings Inc 7.37%$ 7.367 millions
Steris Plc7.33%$ 7.326 millions
Addus Homecare Corp7.22%$ 7.220 millions
Ati Physical Therapy Inc 7.06%$ 7.062 millions
Fennec Pharmaceuticals Inc 7.05%$ 7.045 millions
Gilead Sciences Inc 7.01%$ 7.006 millions
Mountain Crest Acquisition Corp V6.94%$ 6.938 millions
Becton Dickinson And Company6.88%$ 6.880 millions
Vaso Corporation6.72%$ 6.720 millions
Merus N v 6.70%$ 6.698 millions
Orthofix Medical Inc 6.69%$ 6.688 millions


About Revance Therapeutics Inc Revenue Growth Rates (RVNC), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Revance Therapeutics Inc (CIK 1479290).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001479290-24-000128
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Revance Therapeutics Inc ’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.